<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00021801</url>
  </required_header>
  <id_info>
    <org_study_id>dk56953 (completed)</org_study_id>
    <secondary_id>DK56953-01</secondary_id>
    <nct_id>NCT00021801</nct_id>
  </id_info>
  <brief_title>Islet Cell Transplantation Alone and CD34+ Enriched Bone Marrow Cell Infusion in Patients With Diabetes Mellitus: Steroid-Free Regimen</brief_title>
  <official_title>Pathways to Tolerance in Human Islet Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <brief_summary>
    <textblock>
      The goal of islet cell transplantation in Type 1 diabetics is to provide those affected with&#xD;
      constant normal blood glucose levels, thereby reducing or eliminating altogether the need for&#xD;
      injected insulin. This normalization may prevent or slow progression of diabetic&#xD;
      complications, result in a healthier lifestyle, and lead to a better quality of life.&#xD;
&#xD;
      Participants who meet the inclusion criteria will undergo an extensive screening process&#xD;
      which typically includes a series of blood tests, EKG, chest x-rays, and a psychological&#xD;
      evaluation, among others. Those who are eligible for and chose to participate in the trial&#xD;
      will receive an islet cell transplant and bone marrow infusion from the same donor, together&#xD;
      with following immunosuppressive medications: tacrolimus, sirolimus, daclizumab and&#xD;
      infliximab. Because the bone marrow infusion may successfully prevent the transplanted islet&#xD;
      cells from rejecting, some participants may be able to stop taking the immunosuppressive&#xD;
      medications after a year.&#xD;
&#xD;
      The islet cell transplant is done under local anesthesia in a special procedure radiology&#xD;
      room. Several days after the islet cell transplant, the participant is admitted to the&#xD;
      hospital as an outpatient in order to receive bone marrow via a simple intra-venous infusion&#xD;
      procedure.&#xD;
&#xD;
      All participants will need to be seen at the Diabetes Research Institute after the transplant&#xD;
      for follow-up testing and post-islet cell transplant care.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2000</start_date>
  <completion_date>September 2000</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Type 1 Diabetes Mellitus</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Islet Cell Transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Candidates must be between the ages of 18 and 50.&#xD;
&#xD;
          -  Candidates must have had insulin-dependent diabetes mellitus (IDDM) for at least 5&#xD;
             years and been under physician care for at least 6 months prior to enrollment in&#xD;
             trial.&#xD;
&#xD;
          -  Eligible candidates will have poorly controlled IDDM and manifest signs and symptoms&#xD;
             severe enough to be incapacitating. These symptoms can include episodes of&#xD;
             hypoglycemic unawareness (failure to recognize blood glucose levels &lt; 54 mg/dl) or&#xD;
             episodes requiring the assistance of others.&#xD;
&#xD;
          -  Candidates may have poor diabetes control despite intensive insulin therapy (HbA1c &gt;&#xD;
             8.0%).&#xD;
&#xD;
          -  Creatinine clearance should be &gt; 60 ml/min)&#xD;
&#xD;
          -  Body Mass Index should be less than 26&#xD;
&#xD;
          -  Women of child-bearing age must have a negative pregnancy test and agree to follow&#xD;
             effective contraceptive measures for the duration of the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous or concurrent organ transplant&#xD;
&#xD;
          -  Previous or concurrent malignancy&#xD;
&#xD;
          -  Untreated proliferative diabetic retinopathy&#xD;
&#xD;
          -  Unstable cardiovascular status, including positive stress echocardiography (if &gt; age&#xD;
             35)&#xD;
&#xD;
          -  Active infections, including x-ray evidence of pulmonary infection&#xD;
&#xD;
          -  Peptic ulcer disease, gall stones, or portal hypertension&#xD;
&#xD;
          -  Abnormal liver function tests&#xD;
&#xD;
          -  Presence of panel reactive antibodies &gt; 20%&#xD;
&#xD;
          -  Creatinine clearance &lt; 60 ml/min&#xD;
&#xD;
          -  HbA1c &gt; 12%&#xD;
&#xD;
          -  Serological evidence of HIV, HbsAg, or HCV&#xD;
&#xD;
          -  Anemia (hemoglobin &lt; 12.0)&#xD;
&#xD;
          -  Any condition or circumstance, including psychogenic factors, that preclude&#xD;
             therapeutic compliance or otherwise make it unsafe to undergo an islet cell&#xD;
             transplant.&#xD;
&#xD;
          -  PSA &gt; 4 in males&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rodolfo Alejandro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami Diabetes Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami Diabetes Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Alejandro R, Lehmann R, Ricordi C, Kenyon NS, Angelico MC, Burke G, Esquenazi V, Nery J, Betancourt AE, Kong SS, Miller J, Mintz DH. Long-term function (6 years) of islet allografts in type 1 diabetes. Diabetes. 1997 Dec;46(12):1983-9.</citation>
    <PMID>9392484</PMID>
  </reference>
  <verification_date>March 2010</verification_date>
  <study_first_submitted>August 4, 2001</study_first_submitted>
  <study_first_submitted_qc>August 3, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2001</study_first_posted>
  <last_update_submitted>March 1, 2010</last_update_submitted>
  <last_update_submitted_qc>March 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 2, 2010</last_update_posted>
  <keyword>Type I Diabetes Mellitus</keyword>
  <keyword>Immunosuppression</keyword>
  <keyword>Islet Cell Transplant</keyword>
  <keyword>Percutaneous Transhepatic Portal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

